Non-specific Immune Responses And The Impact Of Carboxyamidotriazole Evaluation Of Experimental Colitis In Mice Preventive Effect

Ulcerative colitis (UC) is one of the difficult diseases defined by WHO, the incidence and mortality of it are increasing quickly in China. The routine treatment involves a serial of drugs; however most of them have severe side-effects which limit their usage. Carboxyamidotriazole (CAI) is a new anti-tumor agent without cytotoxicity, and it also shows a high efficiency on anti-inflammatory activity. In this research, the mouse UC model was prepared with3%dextran sulfate sodium on C57/BL strain. In order to find out if CAI (20mg/kg) does any prevention on this model, these criteria are evaluated:body weight, stool change, presence of hemafecia, macroscopic change and pathological change of colons. The damage of colon mucous membrane was scored following HE stain of colon sections. The results show that mice given CAI (20mg/kg) have significant difference compared with PEG400controlled ones. CAI can significantly improve the symptoms of diarrhea and hemafecia caused by UC. Necroscopy findings show alleviated hyperemia, edema and mucous membrane damages in CAI group. A conclusion can be made that CAI (20mg/kg) does prevent animals from experimental acute UC. What’s more, the phagocytosis functions by carbon powder are assessed to find out CAI (20mg/kg) has any influence on non-specific immune function. The results of the index of spleen weight, carbonic expurgation and phagocytosis show no difference which means CAI (20mg/kg) has no influence on non-specific immune function.